Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691154 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
A Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Liquidia Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
- 8
- Study locations
NCT04691154: Active Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Liquidia Technologies.
NCT04691154 is a Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases that is active but no longer recruiting, run by Liquidia Technologies. The registered enrollment target is 28 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04691154, a Phase 3 study of Pulmonary Arterial Hypertension and Pulmonary Hypertension Due to Lung Diseases, is active but no longer recruiting, sponsored by Liquidia Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
- 8
- Study locations
Study Summary
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.
Primary Outcome
(MSP for Cohort A): Proportion of patients with PAH or PH-ILD on a stable Tyvaso dose who would develop treatment-emergent AEs/SAEs after switching to L606 dosing for up to 2 weeks during MSP.
Conditions Studied
Interventions
- COMBINATION_PRODUCT L606 inhalation suspension
Study Locations (8)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of South Florida - Tampa
Arizona
- Arizona Pulmonary Specialists - Scottsdale
California
- VA Greater Los Angeles Healthcare - Los Angeles
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- University of Cincinnati Medical Center - Cincinnati
Oregon
- Summit Health Eastside Clinic - Bend
Texas
- Baylor Scott and White Research Institute - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 3 |
What the registry record for NCT04691154 still lists
NCT04691154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which L606 inhalation suspension is the first listed.
NCT04691154 lists 8 locations in 7 states (Florida, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT04691154 about?
NCT04691154 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD". This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.
What is the current status of trial NCT04691154?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2021-08-01. Estimated completion is 2031-03-31.
What conditions does trial NCT04691154 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases.
What interventions are being tested in trial NCT04691154?
The interventions under investigation include: L606 inhalation suspension (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04691154?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04691154 being conducted?
This trial has 8 study locations across Arizona, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04691154's enrollment target sits among peer trials
28 45th of 63 higher than 19 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
RECRUITING · Phase 3
-
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
ACTIVE NOT RECRUITING · Phase 3
-
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI